Variable | Total 614,100% (n,%) | Average ±SD |
Age (years) | 64.8±10.9 | |
Body mass index (kg/m2) | 30.1±6.9 | |
Overall survival (months) | 74.8±51.4 | |
Disease-free survival (months) | 69.2±53.3 | |
Follow-up (months) | 46.4±24.0 | |
Tumor diameter (mm) | 31.5±18.5 | |
Surgical approach | ||
Laparoscopy | 232 to 37.8% | |
Laparotomy | 296 to 48.2% | |
Vaginal approach | 86 to 14.0% | |
Histological diagnosis | ||
Endometrioid carcinoma | 516 to 84.0% | |
Mucinous carcinoma | 30 to 4.9% | |
Adeno-squamous carcinoma | 23 to 3.7% | |
Mixed neoplasia | 18 to 2.9% | |
Serous carcinoma | 9 to 1.5% | |
Clear cell carcinoma | 9 to 1.5% | |
Other | 9 to 1.5% | |
Type I | 577 to 94.0% | |
Type II | 37 to 6.0% | |
Grading | ||
G1 | 265 to 43.2% | |
G2 | 229 to 37.3% | |
G3 | 120 to 19.5% | |
Myometrial invasion | ||
<50% | 376 to 61.2% | |
≥50% | 238 to 38.8% | |
FIGO stage | ||
IA | 333 to 54.2% | |
IB | 160 to 26.1% | |
II | 47 to 7.7% | |
III | 57 to 9.3% | |
IV | 17 to 2.8% | |
LSVI | ||
Positive | 95 to 15.5% | |
Negative | 519 to 84.5% | |
Lymphadenectomy | ||
None | 330 to 53.7% | |
Pelvic lymphadenectomy | 228 to 37.1% | |
Pelvic and lumboaortic lymphadenectomy | 56 to 9.1% | |
Status of retrieved lymph nodes on 284 lymphadenectomies | ||
Negative | 231 to 81.3% | |
Positive pelvic | 33 to 11,6% | |
Positive lumboaortic | 12 to 4.2% | |
Positive pelvic and lumboaortic | 8 to 2.8% | |
CA 125 | ||
Normal | 484 to 78.8% | |
Abnormal | 130 to 21.2% | |
Radiotherapy | 138 to 22.5% | |
Chemotherapy | 71 to 11.6% | |
Status | ||
Any relapse | 84 to 13.7% | |
Lymph nodal relapse | 15 to 2.4% | |
Pelvic relapse | 33 to 5.4% | |
Distant relapse | 49 to 8.0% | |
Death by disease | 92 to 15.0% | |
Death by other causes | 6 to 1.0% |